‘Xpovio, the first drug introduced by the Chinese pharma company Antengene, has landed in general hospitals.

According to industry sources, the company’s anticancer drug Xpovio (Selinexor) has passed the review of drug committees (DCs) at 4 of the Big 5 tertiary hospitals - Samsung Medical Center (SMC), Seoul National University Hospital (SNUH), Seoul St.Mary’s hospital, Seoul Asan Medical Center (AMC) – and has been added for prescriptions through an emergency DC at the Severance Hospital.

Xpovio, which had been designated as an orphan drug and then approved in August last year, is a drug with a new mechanism of action that selectively inhibits the nuclear export pr